Benzinga - by Benzinga Insights, Benzinga Staff Writer.
In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating UnitedHealth Group (NYSE:UNH) in comparison to its major competitors within the Health Care Providers & Services industry. By analyzing crucial financial metrics, market position, and growth potential, our objective is to provide valuable insights for investors and offer a deeper understanding of company's performance in the industry.
UnitedHealth Group Background UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 53 million members globally, including 5 million outside the U.S. as of mid-2023. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
UnitedHealth Group Inc | 21.86 | 5.11 | 1.32 | 6.1% | $8.66 | $22.0 | 2.24% |
Centene Corp | 15.91 | 1.63 | 0.28 | 0.18% | $0.52 | $3.66 | 3.73% |
Molina Healthcare Inc | 21.40 | 5.57 | 0.69 | 5.34% | $0.36 | $1.04 | 10.03% |
HealthEquity Inc | 239.29 | 3.51 | 7.22 | 0.75% | $0.07 | $0.16 | 15.33% |
Progyny Inc | 80.02 | 7.59 | 3.97 | 3.23% | $0.02 | $0.06 | 36.77% |
Average | 89.16 | 4.58 | 3.04 | 2.38% | $0.24 | $1.23 | 16.46% |
th, td { padding: 8px; text-align: left; }
th { background-color: #293a5a; color: #fff; text-align: left; }
tr:nth-child(even) { background-color: #f2f4f8; }
tr:hover { background-color: #e1e4ea; }
td:nth-child(3), td:nth-child(5) { text-align: left; }
.dividend-amount { font-weight: bold; color: #0d6efd; }
.dividend-frequency { font-size: 12px; color: #6c757d; } After thoroughly examining UnitedHealth Group, the following trends can be inferred:
- At 21.86, the stock's Price to Earnings ratio is 0.25x less than the industry average, suggesting favorable growth potential.
- The elevated Price to Book ratio of 5.11 relative to the industry average by 1.12x suggests company might be overvalued based on its book value.
- The Price to Sales ratio is 1.32, which is 0.43x the industry average. This suggests a possible undervaluation based on sales performance.
- The Return on Equity (ROE) of 6.1% is 3.72% above the industry average, highlighting efficient use of equity to generate profits.
- The company exhibits higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $8.66 Billion, which is 36.08x above the industry average, implying stronger profitability and robust cash flow generation.
- The gross profit of $22.0 Billion is 17.89x above that of its industry, highlighting stronger profitability and higher earnings from its core operations.
-
The company's revenue growth of 2.24% is significantly below the industry average of 16.46%. This suggests a potential struggle in generating increased sales volume.
The debt-to-equity (D/E) ratio measures the financial leverage of a company by evaluating its debt relative to its equity.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
In terms of the Debt-to-Equity ratio, UnitedHealth Group stands in comparison with its top 4 peers, leading to the following comparisons:
- In terms of the debt-to-equity ratio, UnitedHealth Group is positioned in the middle among its top 4 peers.
- This suggests a relatively balanced financial structure, where the company maintains a moderate level of debt while also utilizing equity financing with a debt-to-equity ratio of 0.66.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.